2. Scientific Symposium Opening session CTOS (1 pm to 5 pm)
CTOS reception (5pm to 6pm)
Dinner/Consensus Discussion (6pm to 9 pm)
Panel
George Demetri, MD
Scott Schuetze, MD, PhD
Laurence Baker, DO (moderator)

3. Gleevec G Vs. Gem/TXT STS 219 87
start date
Gleevec
Nov ’01
G Vs. Gem/TXT STS
Jan ’03
Columbia 15 NP
Emory P*
Mayo 6
MD Anderson 45 20
U of Michigan 69 29
Memorial Sloan Kettering 34 11
National Cancer Institute P
Partners
Dana Farber
Massachusetts General 1
UofCalifornia Los Angeles
Washington Cancer Center 14 10
Lutheran General ** 42
Total
219 87
P=Participating NP=Not Participating *Awaiting Contract **No longer accruing

4. CR PR CR PR SD SD PD PD
Month 2
Month 4

5. PRACTICAL ADVANTAGES OF THE BAYESIAN DESIGN
The hierarchical model allows data from each subtype to provide information about parameters in all other subtypes
It avoids two undesirable approaches, conducting :
- One trial, assuming one common parameter, ignoring the subtypes, or
- Separate trials that ignore each others’ data
User-friendly front ends greatly facilitate trial conduct

6. 95% Posterior Credible Intervals by Histologic Subtype
q = Pr( Response )

7. 74 yo man with myofibroblastic sarcoma
Pre-Gleevec
H &. E
8 weeks on Rx
cKIT

8. 65 yo man with malignant fibrous histiocytoma
Pre-Gleevec
H & E
2 weeks on Rx
cKIT

9. Planned Studies Gemcitabine/docetaxel in bone sarcomas
Imatinib neoaduvant treatment of DFSP
AMG 706 Phase II trial in sarcoma
BMS SRC inhibitor
Ziopharm active ifosphamide moiety
Uterine sarcoma adjuvant therapy